Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Other Accumulated Expenses (2016 - 2021)

Historic Other Accumulated Expenses for Anaptysbio (ANAB) over the last 7 years, with Q1 2021 value amounting to $197000.0.

  • Anaptysbio's Other Accumulated Expenses fell 7806.24% to $197000.0 in Q1 2021 from the same period last year, while for Mar 2021 it was $197000.0, marking a year-over-year decrease of 7806.24%. This contributed to the annual value of $342000.0 for FY2020, which is 6073.48% down from last year.
  • As of Q1 2021, Anaptysbio's Other Accumulated Expenses stood at $197000.0, which was down 7806.24% from $342000.0 recorded in Q4 2020.
  • Anaptysbio's Other Accumulated Expenses' 5-year high stood at $925000.0 during Q2 2020, with a 5-year trough of $13000.0 in Q3 2017.
  • For the 5-year period, Anaptysbio's Other Accumulated Expenses averaged around $448466.7, with its median value being $342000.0 (2020).
  • As far as peak fluctuations go, Anaptysbio's Other Accumulated Expenses surged by 350909.09% in 2019, and later plummeted by 7806.24% in 2021.
  • Quarter analysis of 5 years shows Anaptysbio's Other Accumulated Expenses stood at $17000.0 in 2017, then soared by 241.18% to $58000.0 in 2018, then skyrocketed by 1401.72% to $871000.0 in 2019, then plummeted by 60.73% to $342000.0 in 2020, then tumbled by 42.4% to $197000.0 in 2021.
  • Its Other Accumulated Expenses was $197000.0 in Q1 2021, compared to $342000.0 in Q4 2020 and $851000.0 in Q3 2020.